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M A J O R A R T I C L E
Non-O157 Shiga Toxin–Producing Escherichia coli
Infections in the United States, 1983–2002
John T. Brooks,1,a Evangeline G. Sowers,1 Joy G. Wells,1 Katherine D. Greene,1 Patricia M. Griffin,1
Robert M. Hoekstra,2 and Nancy A. Strockbine1
1Foodborne and Diarrheal Diseases Branch and 2Biostatistics and Information Branch, Division of Bacterial and Mycotic Diseases, National Center
for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Background. Shiga toxin–producing Escherichia coli (STEC) O157:H7 is a well-recognized cause of bloody
diarrhea and hemolytic-uremic syndrome (HUS). Non-O157 STEC contribute to this burden of illness but have
been underrecognized as a result of diagnostic limitations and inadequate surveillance.
Methods. Between 1983 and 2002, 43 state public health laboratories submitted 940 human non-O157 STEC
isolates from persons with sporadic illnesses to the Centers for Diseases Control and Prevention reference laboratory
for confirmation and serotyping.
Results. The most common serogroups were O26 (22%), O111 (16%), O103 (12%), O121 (8%), O45 (7%),
and O145 (5%). Non-O157 STEC infections were most frequent during the summer and among young persons
(median age, 12 years; interquartile range, 3–37 years). Virulence gene profiles were as follows: 61% stx1 but not
stx2; 22% stx2 but not stx1; 17% both stx1 and stx2; 84% intimin (eae); and 86% enterohemolysin (E-hly). stx2 was
strongly associated with an increased risk of HUS, and eae was strongly associated with an increased risk of bloody
diarrhea. STEC O111 accounted for most cases of HUS and was also the cause of 3 of 7 non-O157 STEC outbreaks
reported in the United States.
Conclusions. Non-O157 STEC can cause severe illness that is comparable to the illness caused by STEC O157.
Strains that produce Shiga toxin 2 are much more likely to cause HUS than are those that produce Shiga toxin
1 alone. Improving surveillance will more fully elucidate the incidence and pathological spectrum of these emerging
agents. These efforts require increased clinical suspicion, improved clinical laboratory isolation, and continued
serotyping of isolates in public health laboratories.
More than 100 serotypes of Shiga toxin–producing
Escherichia coli (STEC) have been associated with hu-
man disease [1–3], causing illnesses that range from
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mild diarrhea to bloody diarrhea, hemorrhagic colitis,
and hemolytic-uremic syndrome (HUS) [4, 5]. E. coli
O157:H7 is the STEC most frequently isolated in North
America and is the serotype most often associated with
bloody diarrhea and HUS. Non-O157 STEC have al-
so caused sporadic illness and outbreaks of bloody di-
arrhea and HUS, both in the United States [6–10]
and overseas [11–21]. It has been estimated that STEC
O157:H7 causes 73,000 illnesses annually in the United
States and that non-O157 STEC serotypes cause at least
37,000 illnesses [22]. Surveys from North America
demonstrate that STEC causes diarrhea at frequencies
similar to those of other important enteric bacterial
pathogens (e.g., Salmonella and Shigella species), de-
pending on the population studied and its geograph-
ic location, with STEC O157 isolated in one-half of
the illnesses and a variety of non-O157 STEC sero-
types isolated in the other half [23–34]. In continen-
tal Europe, infections with non-O157 STEC serotypes
are more common than infections with O157:H7 STEC
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[35, 36]. Not all non-O157 STEC cause human illness, and
some non-O157 STEC isolates recovered from diarrheal stool
are likely not pathogens. The full spectrum of pathogenic non-
O157 serogroups and the illnesses they cause remain poorly
defined.
When infection with a non-O157 STEC is suspected, clini-
cal laboratories may refer isolates to public health laboratories
for identification and further characterization. The Foodborne
and Diarrheal Diseases Laboratory of the Centers for Diseases
Control and Prevention (CDC) serves as the national reference
laboratory for the confirmation of suspect non-O157 STEC
isolates submitted by clinical laboratories to state and local
public health departments and is one of the few laboratories
in North America with the capacity to serotype confirmed iso-
lates. Until 2000, non-O157 STEC infections were not a na-
tionally notifiable disease. Since 2000, the Council of State and
Territorial Epidemiologists has requested that public health de-
partments report STEC infections to the National Notifiable
Diseases Surveillance System. In the present article, we sum-
marize the data from a large convenience sample of sporadic
human non-O157 STEC isolates from the United States that
have been confirmed by the CDC, describing the frequencies
of serotypes, their seasonality, age distribution, the presence of
various virulence factors, and associations between virulence
factors and clinical syndromes.
SUBJECTS, MATERIALS, AND METHODS
Data collection. We reviewed the records for non-O157 STEC
isolates forwarded by state public health laboratories to the
CDC’s reference laboratory between 1983 and 2002 for con-
firmation and serotyping. The documentation required when
submitting specimens to the CDC included the name of the
submitting state, the date of illness and/or specimen collection,
the source (e.g., stool or blood), and the age and sex of the
person from whom the specimen was collected. A presumptive
diagnosis (e.g., diarrhea or HUS) and illness symptoms were
requested but not required. Some of the isolates included in
this national data set (!10% total) may have been included in
previous analyses from contributing jurisdictions [31, 32, 34,
37]. The present investigation followed the guidelines of the
US Department of Health and Human Services with regard to
the protection of human subjects.
Laboratory procedures. Submitted isolates were streaked
onto tryptose blood plates with washed sheep blood (Smith
River Biologicals) and were incubated at 35C for 18–24 h [38]
The plates were examined at 4 and 18 h for production of
enterohemolysin. Individual colonies, both hemolytic and non-
hemolytic, were then plated on trypticase soy agar with 5%
sheep blood, incubated for 18–24 h, and tested by polymerase
chain reaction for gene sequences encoding the following vir-
ulence factors: Shiga toxins 1 and 2 (stx1 and stx2) [39–41],
intimin (eae) [42], and enterohemolysin (E-hly) [43]. Isolates
that were positive for either or both Shiga toxins were sero-
logically characterized for O and H antigens [44].
Statistical methods. We created a data set with a unique
record for each isolate submitted, eliminating duplicate isolates
that had been submitted from the same person for the same
illness episode. We limited our descriptive analysis to sporadic
disease by excluding any non-O157 STEC isolates that had been
sent to the CDC from the few known US outbreaks. We an-
alyzed dichotomous variables by the x2 test and Fisher’s exact
test and continuous variables by the Wilcoxon rank sum test
(SAS; version 8.0e; SAS Institute). Multivariate analyses were
performed by logistic regression with a backward-elimination
process. We considered associations to be significant if the 95%
confidence interval (CI) excluded 1.0 and (2-tailed).P .05
RESULTS
Between 1983 and 2002, the CDC confirmed 940 non-O157
STEC isolates that had been submitted by 42 state public health
laboratories and the District of Columbia; 866 (92%) of the
isolates were received after 1996 (figure 1). For 801 (85%) iso-
lates, the clinical specimen source was provided: 794 were from
stool, 4 were from urine, and 3 were from blood. The O-groups
for 123 (13%) isolates could not be determined (i.e., they were
nontypeable or formed rough colonies). The remainder in-
cluded 209 (22%) O26:H11 or NM; 152 (16%) O111:H8 or
NM; 117 (12%) O103:H2, H11, H25, or NM; 80 (8%) O121:
H19 or H7; 63 (7%) O45:H2 or NM; 43 (5%) O145:NM; and
147 other isolates from 55 O-groups (each accounting for1%
of all isolates) (table 1). The 6 most common serogroups ac-
counted for 664 (71%) of all isolates. No cases were identified
in which 11 STEC strain was isolated during a single illness
episode. Most isolates were collected during the North Amer-
ican summer, between June and September. Incidence peaked
in August, when 18% of all isolates were collected (figure 2).
Other than this seasonality, there was no other evident clus-
tering of isolates from any serotype in time or space in a fashion
that would have suggested an unrecognized outbreak. We found
no statistically significant differences in the proportional dis-
tributions of the 6 most common serotype north and south of
latitudes 36N and 42N (data not shown).
Of 676 isolates from persons whose sex was included on the
specimen submission form, 372 (55%) were from women. Of
501 (53%) isolates collected from persons for whom age was
provided, the median age was 12 years (interquartile range
[IQR], 3–37 years); 285 (57%) isolates were from persons10
years old. There were 357 persons of known age from whom
isolates belonging to the 6 most common serogroups were iso-
lated. The median age of these persons was significantly lower
than that of the 61 persons with isolates belonging to other
serogroups (10 vs. 21 years; ), after exclusion of 83Pp .04
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Figure 1. Human non-O157 Shiga toxin–producing Escherichia coli (STEC) isolates submitted to the Centers for Disease Control and Prevention for
confirmation, by year, 1983–2002 ( ).np 940
persons of known age from whom non-O157 STEC isolates of
undetermined serogroup were isolated.
Of 292 (31%) isolates submitted with definitive clinical data,
21 (7%) were from persons with HUS and 75 (26%) were from
persons with bloody diarrhea but not HUS (table 2). Data on
age were available for 13 (62%) of the 21 persons from whom
isolates associated with HUS were collected; among these 13,
the median age was 6 years (IQR, 2–10 years). Data on age
were available for 49 (65%) of the 75 persons from whom
isolates associated with bloody diarrhea but not HUS were
collected; among these 49, the median age was 17 years (IQR,
5–51 years).
STEC O111 was the only serogroup statistically associated
with HUS; it was isolated from 10 (48%) of the 21 persons
with HUS, compared with 42 (16%) of the 271 persons without
HUS (relative risk [RR], 4.20 [95% CI, 1.18–9.36]; ).Pp .001
STEC O121 was the only serogroup statistically associated with
bloody diarrhea; it was isolated from 13 (17%) of the 75 persons
with bloody diarrhea but not HUS, compared with 9 (4%) of
the 217 persons without bloody diarrhea (RR, 2.57 [95% CI,
1.71–3.88]; ).Pp .001
Multivariate analyses examining the relationships between
virulence gene profiles (singly and in all permutations, up to
and including the combination of all 4 genes evaluated) and
HUS demonstrated a statistically significant increased risk of
HUS associated with stx2: 20 (93%) of the 21 persons with HUS
provided isolates with detectable stx2, compared with 88 (33%)
of the 271 persons without HUS (estimated odds ratio [OR],
32.0 [95% CI, 4.26–240]; ). Similar analyses demon-Pp .008
strated a statistically significant increased risk of bloody diar-
rhea without HUS associated with eae: 70 (93%) of the 75
persons with bloody diarrhea but without HUS provided iso-
lates with detectable eae, compared with 184 (86%) of the 214
persons without bloody diarrhea (OR 5.26 [95% CI, 1.60–17.3];
). All associations remained robust and of comparablePp .006
magnitude when the univariate and multivariate analyses in-
cluded all isolates, regardless of clinical data.
DISCUSSION
This comprehensive evaluation of non-O157 STEC isolates
from persons in the United States found that 6 (O26, O111,
O103, O121, O45, and O145) of the 61 serogroups identified
accounted for 71% of the isolates recovered from 1983 to 2002.
Three of these serogroups (O26, O111, and O103) accounted
for 50% of the isolates. The non-O157 STEC demonstrated a
summer seasonality, similar to that for the STEC O157:H7 [45,
46], and were isolated more frequently from children.
The virulence gene stx2 was significantly associated with an
increased risk of HUS in persons infected with non-O157 STEC
in the United States, which is consistent with similar findings
reported from the United Kingdom [47]. Surveys have shown
that the vast majority of North American STEC O157:H7 iso-
lates associated with HUS possess stx2 alone or in combination
with stx1 and that only a small fraction possess stx1 but not stx2
[4, 46, 48]; we found a similar distribution of Shiga toxin genes
among the non-O157 STEC isolates associated with HUS. Stud-
ies conducted elsewhere in the world examining the association
between HUS and virulence factors in STEC collections, some
of which included O157:H7, have similarly shown that stx2 is
the factor most strongly associated with the development of
HUS [20, 47, 49–54]. Although the mechanism by which Shiga
toxin 2 causes HUS is not fully understood, the active site of
this molecule is considerably more accessible than the active
site of Shiga toxin 1, which may explain the stronger association
between this virulence factor and disease [55].
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Table 1. Human non-O157 Shiga toxin–producing Escherichia coli isolates submitted to the Centers for Disease Control and Prevention






eae E-hlystx1 alone stx2 alone stx1 and stx2
O26 (n p 209) 6 (2–18) 182/208 (88) 4/208 (2) 22/208 (11) 198/202 (98) 195/202 (96)
O111 (n p 152) 6 (2–21) 65/152 (43) 0/152 (0) 87/152 (57) 146/149 (98) 139/149 (93)
O103 (n p 117) 17 (3–31) 117/117 (100) 0/117 (0) 0/117 (0) 115/115 (100) 114/115 (99)
O121 (n p 80) 10 (4–34) 1/80 (1) 72/80 (90) 7/80 (9) 73/75 (97) 69/75 (92)
O45 (n p 63) 25 (13–48) 62/63 (98) 0/63 (0) 1/63 (2) 62/63 (98) 60/63 (95)
O145 (n p 43) 18 (6–42) 18/43 (42) 19/43 (44) 6/43 (14) 42/42 (100) 42/42 (100)
O165 (n p 14) 20 (8–66) 0/14 (0) 7/14 (50) 7/14 (50) 13/14 (93) 13/14 (93)
O118 (n p 9) 36 (2–52) 9/9 (100) 0/9 (0) 0/9 (0) 8/8 (100) 8/8 (100)
O91 (n p 8) 42 (30–46) 4/8 (50) 1/8 (12) 3/8 (38) 0/8 (0) 4/8 (50)
O113 (n p 8) 19 (10–41) 0/8 (0) 6/8 (75) 2/8 (25) 0/8 (0) 5/8 (62)
O153 (n p 7) 10 (9–11) 7/7 (100) 0/7 (0) 0/7 (0) 7/7 (100) 7/7 (100)
O146 (n p 6) 69 (64–74) 5/6 (83) 1/6 (17) 0/7 (0) 0/6 (0) 2/6 (33)
O174 (n p 6) 51 (21–75) 0/6 (0) 6/6 (100) 0/6 (0) 0/6 (0) 0/6 (0)
Other (n p 95)b 27 (7–62) 29/95 (30) 46/95 (48) 20/95 (20) 29/94 (31) 39/93 (42)
Undetermined (n p 123) 27 (7–62) 71/123 (58) 38/123 (31) 14/123 (11) 82/121 (68) 96/121 (79)
Total (n p 940) 15 (5–41) 570/939 (61) 200/939 (21) 169/939 (18) 775/918 (84) 793/917 (86)
NOTE. Data are proportion (%) of isolates, unless otherwise noted. IQR, interquartile range.
a For isolates for which the age of the person providing the specimen was included with submission to the CDC.
b For O22, O28, and O88, 5 isolates each (!1%); for 0119, O128, and O172, 4 isolates each (!1%); for O6, O8, O60, O63, O104, O117, and O126, 3 isolates
each (!1%); for O2, O14, O49, O50, O55, O73, O75, O96, O109, O110, O137, and O163, 2 isolates each (!1%); and for O1, O4, O5, O21, O38, O46, O48,
O51, O77, O79, O83, O84, O86, O116, O124, O125, O140, O142, O143, O159, O168, O171, and O53/O117, 1 isolate each (!1%).
We also identified an independent association between eae
and bloody diarrhea; eae encodes the protein intimin, which
facilitates attaching and effacing lesions on the gut epithelium
and may explain, in part, the association between this virulence
factor and bloody diarrhea. Bloody diarrhea has also been as-
sociated with stx2, with or without other factors [52, 56]. The
association with stx2 remains controversial [34, 57], with some
authors proposing that the bloody diarrhea observed during
STEC infections may more likely be related to virulence factors
other than Shiga toxins [34, 58].
Our data demonstrate that STEC O111 is the second most
common bacterial cause of HUS in the United States, after
STEC O157:H7. STEC O111 was identified as the etiological
agent for 3 of 7 reported outbreaks of non-O157 STEC sero-
types; 2 of the STEC O111 outbreaks included cases of HUS.
Eleven (52%) of the 21 non-O157 STEC isolates associated
with HUS were STEC O111; none were isolates from the 3
recognized outbreaks. An association between STEC O111 and
HUS has also been observed in other countries [59].
The association we observed between HUS and stx2 was not,
however, a marker for infection with STEC O111, even though
9 (90%) of the 10 STEC O111 isolates associated with HUS
were stx2 positive. Our multivariate analysis included as vari-
ables only virulence genes, which (like other investigators) we
believe to be the driving force in the etiology of STEC-associ-
ated illness. When serotype was included in the multivariate
models, we were not surprised to find a statistically significant
association between HUS and STEC O111 (OR 2.89 [95% CI
1.15–7.23]; ); however, the association between HUSPp .024
and stx2 remained robust and was more significant (OR, 27.2
[95% CI, 3.60–205]; ).Pp .001
We did not receive submissions from cases of illness yield-
ing 2 or more different STEC isolates. The lack of these cases
in our collection is likely due, in large part, to common cul-
turing practices that are not sensitive enough to recover 11
different STEC isolate from a stool specimen. Studies are
needed to evaluate specimens for mixed STEC infections and
to assess the prevalence of such infections, particularly their
association with severe illness.
Our survey was limited to isolates sent to the CDC reference
laboratory and does not represent the results of formal sur-
veillance. Nonetheless, this large convenience sample provides
the most informative data on non-O157 STEC infections in
the United States. A convenience sample is subject to a number
of biases. Most infections are not detected, because clinical
laboratories do not test specimens for non-O157 STEC. Con-
versely, laboratories equipped to identify STEC may have iso-
lated strains and not sent them to the CDC. However, the
number of non-O157 STEC isolates not submitted to the CDC
was likely small, because most US clinical and public health
laboratories lacked the resources for serotyping E. coli during
the survey period. It is likely that some clinical laboratories
identified Shiga toxin–positive specimens but did not submit
an isolate for serotyping. Although we cannot assess the extent
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Table 2. Prevalence of virulence genes among 21 human non-O157 Shiga toxin–producing Esch-
erichia coli (STEC) isolates associated with hemolytic-uremic syndrome (HUS) and 75 non-O157
STEC isolates associated with bloody diarrhea, 1983–2002.
Disease, serogroup
Shiga toxin
eae E-hlystx1 alone stx2 alone stx1 and stx2
HUS
O111 (n p 10) 1/10 (10) 0/10 (0) 9/10 (90) 9/9 (100) 8/9 (89)
Othera (n p 11) 0/11 (0) 8/11 (73) 3/11 (27) 7/11 (64) 8/11 (73)
Total (n p 21) 1/21 (5) 8/21 (38) 12/21 (57) 16/20 (80) 16/20 (80)
Bloody diarrhea
O26 (n p 12) 10/12 (83) 0/12 (0) 2/12 (17) 12/12 (100) 12/12 (89)
O111 (n p 8) 4/8 (50) 0/8 (0) 4/8 (50) 7/8 (88) 8/8 (100)
O103 (n p 12) 12/12 (100) 0/12 (0) 0/12 (0) 12/12 (100) 12/12 (100)
O121 (n p 13) 0/13 (0) 13/13 (100) 0/13 (0) 12/13 (92) 12/13 (92)
O45 (n p 10) 10/10 (100) 0/10 (0) 0/10 (0) 10/10 (100) 9/10 (90)
O145 (n p 4) 1/4 (25) 2/4 (50) 1/4 (25) 4/4 (100) 4/4 (100)
Otherb (n p 9) 3/9 (33) 5/9 (56) 1/9 (11) 6/9 (67) 6/9 (67)
Undetermined (n p 7) 6/7 (86) 0/7 (0) 1/7 (14) 7/7 (100) 7/7 (100)
Total (n p 75) 46/75 (61) 20/75 (27) 9/75 (12) 70/75 (93) 70/75 (93)
NOTE. Data are proportion (%) of isolates.
a For O14, O22, O26, O50, O79, O113, O121, O137, O145, O165, and O172, 1 isolate each.
b For O8, O49, O79, O117, O118, O137, O140, O143, and O165, 1 isolate each.












1990 O111 Ohio 5 Yes Undetermined Yes No [7]
1994 O104 Montana 18 Yes Milk No No [6]
1999 O121 Connecticut 11 Yes Lake water Yes No [60]
1999 O111 Texas 56 Yes Salad bar Yes No [10]
2000 O103 Washington 18 Yes Punch Yes No Unpublisheda
2001 O111 South Dakota 3 No Day care No No [61]
2001 O26 Minnesota 4 No Lake water No No Unpublisheda
NOTE. HUS, hemolytic-uremic syndrome.
a Unpublished data reported to the Centers for Disease Control and Prevention (presented with permission from the Washington State Department of Health
and the Minnesota Department of Public Health).
of this activity, we have no reason to believe that there was a
systematic exclusion bias that would have altered the distri-
bution of serogroups we describe here. Formal surveillance
could ameliorate these biases and provide more-informative
data by better describing the spectrum of STEC serotypes that
cause disease, their frequency and geographic distribution, and
the clinical illness they cause.
We received clinical data for only one-third of specimens;
we assumed that the isolates we received were forwarded to
public health laboratories by clinical facilities for the diagnos-
tic evaluation of illness. Although both diarrhea and HUS are
well-characterized conditions, use of a standardized diagnosis
on the specimen submission form was not required; the di-
agnoses included on the forms were assigned at the discretion
of the submitter on the basis of available clinical information,
which may have been limited and led to underreporting. Di-
agnosis of non-O157 STEC infection may have been pursued
more aggressively in very ill persons, particularly those with
bloody diarrhea or HUS. A high proportion of isolates that
were included in small, previous series were from patients with
more-severe illness [34], suggesting that some of the patients
with missing clinical data also had severe illness. This classi-
fication error would alter the statistical associations of HUS
and bloody diarrhea with non-O157 serogroups and virulence
factors we observed; however, without better clinical data, we
cannot speculate reliably to what degree. The associations we
found are consistent with the findings of previous reports and
are biologically plausible. The present study was unable to an-
alyze important questions regarding the clinical care of persons
with STEC infection, such as the benefit or harm resulting from
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Figure 2. Human non-O157 Shiga toxin–producing Escherichia coli isolates submitted to the Centers for Disease Control and Prevention for
confirmation, by month of illness onset or specimen collection, 1983–2002 ( ).np 940
the use of antibiotics in the treatment of non-O157 STEC in-
fection; clinical complications of these infections other than
HUS (e.g., stroke); length of illness; and period of bacterial
shedding. At a minimum, future surveillance-based case re-
porting of non-O157 STEC infections should indicate defini-
tively whether bloody diarrhea and HUS were present or absent
by use of standardized definitions.
The present study included only sporadic infections with non-
O157 STEC. From 1992 to 2002, 7 outbreaks of non-O157 STEC
infections were reported in the United States (table 3); 5 were
serologically confirmed. Three were caused by STEC O111, and
1 each was caused by STEC O26, O103, O104, and O121. Ep-
idemiologic investigation associated 6 outbreaks with specific ex-
posures (3 foodborne and 3 environmental); however, a vehicle
was microbiologically confirmed in none. Improved surveillance
and awareness of non-O157 STEC as pathogens will improve the
identification and reporting of outbreaks, which may be currently
underrecognized.
Most non-O157 STEC cannot be visually distinguished from
nonpathogenic E. coli on differential plating media (e.g., sor-
bitol MacConkey’s agar [SMAC]), which until recently was the
principal method used to screen bloody diarrhea and specimens
from persons with HUS for STEC O157:H7. O157:H7 colonies
appear pale, whereas other E. coli, including most non-O157
STEC, appear pink. Screening for non-O157 STEC has been
facilitated by new assays that detect Shiga toxin; submission of
non-O157 STEC isolates to the CDC for confirmation increased
substantially after the commercial introduction of Shiga tox-
in EIAs (figure 1). Notably, simultaneous culture of stools on
SMAC and screening for Shiga toxin by EIA has identified more
STEC than has either procedure alone [33, 62].
The advent of Shiga toxin EIAs has substantially increased
the capacity of community-based laboratories to diagnose non-
O157 STEC infections. Before the mid-1990s, diagnosis was
limited to a few academic and public health laboratories with
specialized capacity. Although the 74 isolates received before
the mid-1990s may be less representative of community-based
illness, we have presented data from both before and after the
development of Shiga toxin EIAs to illustrate how these assays
can enhance routine surveillance for non-O157 STEC. The pro-
portional distribution of serotypes among the 866 isolates re-
ceived during the period 1997–2002 was not significantly dif-
ferent from that among all 940 isolates. Inclusion of isolates
from both periods would not affect our analysis of the associ-
ations between clinical syndromes and virulence factors.
Although direct testing of stool by use of these EIAs to detect
the presence of Shiga toxin–producing bacteria might seem to
obviate the clinical need to culture stool, the importance of
obtaining STEC isolates for public health surveillance cannot
be overemphasized. Non-O157 STEC may be as common a
cause of diarrhea as other, better recognized bacterial agents.
Notably, most of the isolates we received from persons de-
scribed as having diarrhea were not described as having either
bloody diarrhea or HUS, and these persons may have presented
with clinical symptoms similar to those of infections with oth-
er enteric pathogens. The low infectious dose of some non-
O157 STEC genotypes and their potential to cause severe life-
threatening illness, particularly among children, make these
agents an important public health concern. For this reason, it
is essential that Shiga toxin–positive specimens or isolates be
forwarded to public health laboratories for serological and mo-
lecular characterization of the Shiga toxin–producing organ-
isms; identification of the toxin alone is inadequate and should
not be used to replace culture and serotyping.
Improved national surveillance will advance our understand-
ing of the epidemiology of non-O157 STEC infections and
allow us to monitor changes in the frequency with which major
serogroups cause illness over time. We strongly encourage cli-
nicians to consider STEC infection when diagnosing illnesses
and clinical laboratories to consider screening all specimens
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from persons with diarrhea for STEC, both O157 and non-
O157. If screening all specimens for non-O157 STEC is im-
practical, then we advise, at a minimum, evaluating specimens
from persons with bloody diarrhea or HUS; this practice could
be reserved for specimens that do not yield STEC O157. Mo-
lecular methods, such as Shiga toxin EIAs, should be used in
tandem with culture and serotyping and never alone. At this
time, isolating and serotyping E. coli isolates that are positive
for Shiga toxin is the only way to monitor trends, to detect
emerging STEC serotypes, and to define their epidemiology.
Providing public health laboratories with the expertise and an-
tisera needed to identify STEC that belong to the 6 major non-
O157 serogroups is a first step that could speed the identifi-
cation of outbreaks and improve our overall understanding of
STEC.
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